| 000 | 02146cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030916.0 | ||
| 008 | 131219s2013 ua f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.04.Ph.D.2013.He.R | ||
| 100 | 0 | _aHeba Aly Mohamed Ateya | |
| 245 | 1 | 4 |
_aThe role of neoadjuvant aromatase inhibitors in ER / PR positive HER-2 neu negative in postmenopausal females with locally advanced breast cancer / _cHeba Aly Mohamed Ateya ; Supervised Heba M. Elzawahry , Nadia Mahmoud Mokhtar , Osman M. Mansour |
| 246 | 1 | 5 | _aدور مثبطات الارومازين فى العلاج ما قبل الجراحة فى حالات فى حالات سرطان الثدى المتقدم موضعيا فى السيدات بعد سن الياس ذوات مستقبلات الاستروجين / البروجستيرون الموجبة والهيرتو نيو السالبة |
| 260 |
_aCairo : _bHeba Aly Mohamed Ateya , _c2013 |
||
| 300 |
_a188 P. ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) | ||
| 520 | _aBackground: In Egypt female breast cancer ranks as the first malignancy affecting females (37.5% in NCI Egypt). Approximately 20% to 25% of breast cancer patients present with locally advanced disease. Methods : this is a prospective study including fifty two female postmenopausal patients with newly diagnosed LABC, they receive 4 months of neoadjuvant aromatase inhibitor (letrozole) 2.5 mg daily followed by clinical and radiological evaluation, if they have at least partial response, they will be refered to surgery | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAromatase inhibitors | |
| 653 | 4 | _alocally advanced breast cancer | |
| 653 | 4 | _aNeoadjuvant | |
| 700 | 0 |
_aHeba Mohamed Elzawahry , _eSupervisor |
|
| 700 | 0 |
_aNadia Mahmoud Mokhtar , _eSupervisor |
|
| 700 | 0 |
_aOsman Mohamed Mansour , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aAml _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c44508 _d44508 |
||